Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Latigo Biotherapeutics
Biotech
Latigo saddles up with $150M to advance non-opioid pain assets
Latigo will use the raise to move its Nav1.8 inhibitors LTG-001 and LTG-305 through the clinic as it races to catch up with rival Vertex.
Darren Incorvaia
Mar 17, 2025 5:00am
CRO Lotus' founder leaps to Latigo
Aug 20, 2024 1:59pm
Moderna, Terremoto, MEI Pharma and more—Chutes & Ladders
Jul 26, 2024 8:30am
Foresite raises $900M to make fresh set of big biotech bets
Jun 12, 2024 9:00am
Latigo raises $135M to catch up to Vertex in chronic pain
Feb 14, 2024 5:00am
